Pharmaceutical Commerce

🚨Our June issue is LIVE🚨 This month, we explore: ▪️Ways to navigate disruption by building #agility and #adaptability into #pharma operations ▪️Reinventing #supplychainmanagement with #RWD ▪️Changing the #PAP model ▪️A review of the #MFN model Catch these topics and much more at the interactive link here: https://lnkd.in/gZ_uRQdq You can also check out the HTML version here: https://lnkd.in/gqjZF3vp

‼️ The FDA has launched its PreCheck program to accelerate US drug manufacturing approvals and reduce reliance on foreign production. The two-phase process streamlines facility readiness and application review, aiming to strengthen the domestic supply chain amid rising tariffs and increased reshoring investments from major pharma companies. With over 50% of U.S. pharmaceuticals produced overseas and only 11 API manufacturers based domestically, PreCheck could be a pivotal step toward greater manufacturing resilience. https://lnkd.in/gbuDAtME #FDAPreCheck #PharmaManufacturing #SupplyChain #APIs #DrugManufacturing #PharmaPolicy #Reshoring #Biopharma #Tariffs

President Trump has signaled that pharmaceutical import tariffs could climb as high as 250%, intensifying pressure on drugmakers to rethink supply chains. Along with that, the Trump administration early this morning enacted tariff rates between 10% to 50% on a multitude of trading partners. A majority of goods entering the United States will have a baseline levy of 10%. We also can't forget the MFN drug pricing model. While it draws criticism for potentially stifling innovation, companies are already moving to mitigate risk: AstraZeneca, Regeneron, Roche, Merck, Thermo Fisher Scientific, and others have announced major US manufacturing and R&D investments totaling tens of billions of dollars. These moves aim to strengthen domestic production, protect supply chain resilience, and position the industry for long-term policy shifts. The latest via Pharmaceutical Commerce ⬇️ https://lnkd.in/ezhyZ5DF #Pharma #DrugPricing #Tariffs #Manufacturing #SupplyChain #Reshoring #PharmaPolicy #Biopharma #USManufacturing #TradePolicy

Unlocking Strategies for Navigating the Evolving Market Access Landscape Check out our latest Peer Exchange® that centers on navigating the complexities of drug pricing, market access, and reimbursement through the balance of regulatory, payer, and patient perspectives. Watch now:https://hubs.li/Q03BLx120

As pharmacy deserts expand across the US, in-store pharmacies are stepping up—offering point-of-care testing, immunizations, chronic disease management, and even nutrition counseling just steps from the produce aisle. 🎙️ In our latest Pharma Pulse podcast, we explore how these community-based health hubs are transforming access through: 🔵 Clinical services embedded in retail settings 🔵 Real-time patient education powered by in-store digital tools 🔵 AI-driven content personalization and health literacy support This isn’t just convenient, it’s a scalable solution to bridge care gaps in underserved areas. 📍 Listen now: Redefining the Pharmacy Aisle https://lnkd.in/eTrSgGhd #PharmaPulse #PharmacyDeserts #RetailHealth #PatientAccess #DigitalHealth #HealthEquity #PointOfCare #HealthcareInnovation

Don’t just attend the conference. Own it. Conference Insider gives your brand premium visibility during the event — with daily coverage, key opinion leader interviews, and expert recaps that put your company in front of the right audience. Conference Connect extends your impact after the show — through custom editorialized video content that builds brand recognition, highlights thought leaders, and strengthens post-event engagement. Engage. Elevate. Extend your ROI. Learn more: https://hubs.li/Q03BxSCN0

🚨 Novo Nordisk has filed 14 new lawsuits, part of a broader effort spanning 132 federal complaints across 40 states, to crack down on pharmacies and telehealth companies selling unapproved compounded semaglutide products under misleading claims. These knockoffs, often made with unregulated foreign APIs, have been linked to serious safety risks, including patient overdoses. Courts have already issued 44 permanent injunctions and ordered profit forfeitures in similar cases. As compounded GLP-1 products gain traction, this legal battle highlights the urgent need for regulatory clarity and public awareness. https://lnkd.in/e-tryZaq #Semaglutide #GLP1 #NovoNordisk #PharmaRegulation #DrugSafety #CompoundingPharmacy #Telehealth #WeightLossDrugs #Ozempic #Wegovy #FDA

🔵 Noom has launched its Microdose GLP-1Rx Program to improve affordability and reduce side effects tied to weight loss medications. The $119 starter plan includes access to compounded semaglutide (0.6 mg max), clinical support, and behavioral coaching via the company’s GLP-1 Companion platform. With over 50% of GLP-1 users discontinuing due to cost and 36% due to side effects, Noom’s “low and slow” titration strategy could offer a more sustainable path to weight loss. https://lnkd.in/ewTa5R3x #GLP1 #Noom #ObesityTreatment #DigitalHealth #WeightLoss #Semaglutide #HealthTech #CompoundedDrugs #PharmaInnovation #BehavioralHealth

💡 Pharma Supply Chain Hits “Go” on DSCSA Readiness As DSCSA enforcement goes live, the pharma industry shifts from trial-and-error to full activation. In a new interview with Pharma Commerce, Cencora’s Heather Zenk highlights how exception management and real-time response are now mission-critical to keeping life-saving medications flowing. “We’ve pushed, pulled, failed, and reset. Now, it’s go time,” says Zenk. https://lnkd.in/eEDW7sta #DSCSA #PharmaSupplyChain #Compliance #HealthcareLogistics

President Trump has sent formal letters to 17 of the world’s largest pharmaceutical companies, demanding US drug prices match the lowest globally, triggering a 60-day compliance deadline. The move has prompted immediate global responses, including from South Korea’s Celltrion Inc, which announced a multi-phase plan to mitigate tariff exposure and expand US manufacturing. https://lnkd.in/eDZwcKvu #Pharma #DrugPricing #HealthcarePolicy #MFN #SupplyChain #Biosimilars #Tariffs #PharmaceuticalIndustry